FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2566266688> ?p ?o ?g. }

• W2566266688 abstract "The discovery of cancer-driver mutations, accounting for the growth and spreading of cancer cells, led to the development of anti-cancer targeted therapies, which hit in a specific manner cell pathways directly involved in tumor progression. This new class of therapeutic agents has been shown to be more effective and less toxic than conventional chemotherapy in advanced forms of cancer. However, the inevitable development of acquired resistance has limited their success. An example of this concept is the case of Epidermal Growth Factor Receptor (EGFR)-mutant lung cancer. The discovery of EGFR mutations that confer sensitivity to the Tyrosine Kinase Inhibitors (TKI) erlotinib and gefitinib have underlined the importance of defining molecular subgroups to design more efficacious targeted therapies. Unfortunately, on average ~1 year after starting treatment, resistance to these agents, caused by EGFR secondary mutation T790M, occurs at high frequency. This observation suggests that strategies to delay or prevent the emergence of this resistance mechanism would prolong the lives of many lung cancer patients with EGFR mutations. AZD9291 and CO-1686 are two novel third-generation EGFR TKIs designed to irreversibly and specifically target both the initial activating EGFR mutations and the resistance T790M. Phase I/II studies show compelling clinical activity of these compounds. Nevertheless the observed progression-free survival is about 12 months and the reasons of the relapse are under evaluation. We took advantage of a lentiviral vector (LV) -based insertional mutagenesis platform, developed by our lab, to screen genes that confer resistance to CO-1686. To this aim T790M+ (PC9BRc1) and T790M- (PC9) human lung adenocarcinoma cells were transduced with a genotoxic LV, harboring the Spleen Focus Forming Virus enhancer/promoter in the Long Terminal Repeats (LV-SF-LTR) or a non-genotoxic LV with self-inactivating LTR. After 2 weeks, transduced cells were divided in three groups receiving Erlotinib, CO-1686 or DMSO as control. In our rationale, the integration of the genotoxic LV in the cellular genome can potentially deregulate the expression of neighboring genes that contribute to confer resistance to these TKIs. Therefore, exposure to the treatment would result in the selection and expansion of the cell clones harboring those specific traceable mutations. Drug-resistant colonies were obtained after 4 weeks of erlotinib and 6 weeks of CO-1686 treatment. While results on PC9BRc1 are still pending, sequencing analysis performed on 100,000 LV integration sites retrieved by PCR-based technologies on PC9 drug-resistant colonies identified SOS1 as the principal LV-induced gene deregulation responsible for the resistance to both Erlotinib and CO-1686. A similar experiment aimed at identifying the AZD9291-induced resistance in lung cancer cells is on-going. The identification of biomarkers of resistance will allow the development of new therapies to overcome resistance, improving the life expectancy of lung adenocarcinoma patients." @default.
• W2566266688 created "2017-01-06" @default.
• W2566266688 creator A5009057517 @default.
• W2566266688 creator A5014403156 @default.
• W2566266688 creator A5014559198 @default.
• W2566266688 creator A5031944701 @default.
• W2566266688 creator A5033693548 @default.
• W2566266688 creator A5070225906 @default.
• W2566266688 date "2016-05-01" @default.
• W2566266688 modified "2023-09-27" @default.
• W2566266688 title "212. Lentiviral Insertional Mutagenesis Helps to Uncover the Mechanisms of Resistance to AZD9291 and CO-1686 in EGFR-Mutant Lung Adenocarcinoma" @default.
• W2566266688 doi "https://doi.org/10.1016/s1525-0016(16)33021-0" @default.
• W2566266688 hasPublicationYear "2016" @default.
• W2566266688 type Work @default.
• W2566266688 sameAs 2566266688 @default.
• W2566266688 citedByCount "0" @default.
• W2566266688 crossrefType "journal-article" @default.
• W2566266688 hasAuthorship W2566266688A5009057517 @default.
• W2566266688 hasAuthorship W2566266688A5014403156 @default.
• W2566266688 hasAuthorship W2566266688A5014559198 @default.
• W2566266688 hasAuthorship W2566266688A5031944701 @default.
• W2566266688 hasAuthorship W2566266688A5033693548 @default.
• W2566266688 hasAuthorship W2566266688A5070225906 @default.
• W2566266688 hasBestOaLocation W25662666881 @default.
• W2566266688 hasConcept C104317684 @default.
• W2566266688 hasConcept C107635520 @default.
• W2566266688 hasConcept C121608353 @default.
• W2566266688 hasConcept C143065580 @default.
• W2566266688 hasConcept C143998085 @default.
• W2566266688 hasConcept C16318435 @default.
• W2566266688 hasConcept C2776256026 @default.
• W2566266688 hasConcept C2777626846 @default.
• W2566266688 hasConcept C2777930144 @default.
• W2566266688 hasConcept C2778087573 @default.
• W2566266688 hasConcept C2779438470 @default.
• W2566266688 hasConcept C2780580887 @default.
• W2566266688 hasConcept C501734568 @default.
• W2566266688 hasConcept C502942594 @default.
• W2566266688 hasConcept C54355233 @default.
• W2566266688 hasConcept C71924100 @default.
• W2566266688 hasConcept C86803240 @default.
• W2566266688 hasConceptScore W2566266688C104317684 @default.
• W2566266688 hasConceptScore W2566266688C107635520 @default.
• W2566266688 hasConceptScore W2566266688C121608353 @default.
• W2566266688 hasConceptScore W2566266688C143065580 @default.
• W2566266688 hasConceptScore W2566266688C143998085 @default.
• W2566266688 hasConceptScore W2566266688C16318435 @default.
• W2566266688 hasConceptScore W2566266688C2776256026 @default.
• W2566266688 hasConceptScore W2566266688C2777626846 @default.
• W2566266688 hasConceptScore W2566266688C2777930144 @default.
• W2566266688 hasConceptScore W2566266688C2778087573 @default.
• W2566266688 hasConceptScore W2566266688C2779438470 @default.
• W2566266688 hasConceptScore W2566266688C2780580887 @default.
• W2566266688 hasConceptScore W2566266688C501734568 @default.
• W2566266688 hasConceptScore W2566266688C502942594 @default.
• W2566266688 hasConceptScore W2566266688C54355233 @default.
• W2566266688 hasConceptScore W2566266688C71924100 @default.
• W2566266688 hasConceptScore W2566266688C86803240 @default.
• W2566266688 hasLocation W25662666881 @default.
• W2566266688 hasOpenAccess W2566266688 @default.
• W2566266688 hasPrimaryLocation W25662666881 @default.
• W2566266688 hasRelatedWork W1975982719 @default.
• W2566266688 hasRelatedWork W1983135402 @default.
• W2566266688 hasRelatedWork W1987575156 @default.
• W2566266688 hasRelatedWork W2065141010 @default.
• W2566266688 hasRelatedWork W2084089300 @default.
• W2566266688 hasRelatedWork W2399922602 @default.
• W2566266688 hasRelatedWork W2407280987 @default.
• W2566266688 hasRelatedWork W2524147766 @default.
• W2566266688 hasRelatedWork W2563039219 @default.
• W2566266688 hasRelatedWork W2591896511 @default.
• W2566266688 hasRelatedWork W2745035390 @default.
• W2566266688 hasRelatedWork W2811390231 @default.
• W2566266688 hasRelatedWork W2887298079 @default.
• W2566266688 hasRelatedWork W2887381522 @default.
• W2566266688 hasRelatedWork W2952014247 @default.
• W2566266688 hasRelatedWork W2964016456 @default.
• W2566266688 hasRelatedWork W3102683919 @default.
• W2566266688 hasRelatedWork W3181898261 @default.
• W2566266688 hasRelatedWork W841794138 @default.
• W2566266688 hasRelatedWork W996184470 @default.
• W2566266688 isParatext "false" @default.
• W2566266688 isRetracted "false" @default.
• W2566266688 magId "2566266688" @default.
• W2566266688 workType "article" @default.